Correlates of protection to influenza virus, where do we go from here?

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 2, 2013, Pages 405-408

  Cox, Rebecca J ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Correlate protection; Influenza

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; BIOLOGICAL MARKER;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; B LYMPHOCYTE; CELL ASSAY; CORRELATION ANALYSIS; ERYTHROCYTE; EXPERIMENTAL MODEL; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LABORATORY TEST; LICENCE; NONHUMAN; REVIEW; SEROCONVERSION; STANDARDIZATION; T LYMPHOCYTE; TREATMENT RESPONSE; VIRUS STRAIN; BLOOD; IMMUNOASSAY; IMMUNOLOGY; INFLUENZA, HUMAN; PROCEDURES; REPRODUCIBILITY; STANDARDS; STATISTICS;

ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; HUMANS; IMMUNOASSAY; INFLUENZA VACCINES; INFLUENZA, HUMAN; REPRODUCIBILITY OF RESULTS; STATISTICS AS TOPIC;

EID: 84874674301     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22908     Document Type: Review

References (29)

1. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44; PMID:22032844; http://dx.doi.org/10.1016/ S1473-3099(11)70295-X.
2. Ainsworth MA. New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role. Ugeskr Laeger 2003 165:1648-9; PMID:12756819.
3. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767-77; PMID:4509641; http://dx.doi.org/10.1017/S0022172400022610.
4. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979 35:69-75; PMID:367490. (Pubitemid 9096975)
5. Al-Khayatt R, Jennings R, Potter CW. Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis. J Hyg (Lond) 1984; 93:301-12; PMID:6389697; http://dx.doi.org/10.1017/S0022172400064834. (Pubitemid 15207959)
6. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010; 10:18; PMID:20210985; http://dx.doi.org/10.1186/1471-2288-10-18.
7. Davies JR, Grilli EA. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 1989; 102:325-33; PMID:2703026; http://dx.doi.org/10.1017/ S0950268800030004. (Pubitemid 19106053)
8. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011; 30:1081-5; PMID:21983214; http://dx.doi.org/10.1097/INF.0b013e3182367662.
9. Wagner R, Gopfert C, Hammann J, Neumann B, Wood J, Newman R, et al. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach. Vaccine 2012; 30:4113-22; PMID:22446639; http://dx.doi.org/10.1016/j. vaccine.2012.02.077.
10. Wood JM, Major D, Heath A, Newman RW, Hoschler K, Stephenson I, et al. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine 2012; 30:210-7; PMID:22100887; http://dx.doi.org/10.1016/j.vaccine.2011.11.019.
11. Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009; 15:1252-9; PMID:19751587; http://dx.doi.org/10.3201/eid1508.081754.
12. Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994; 12:167-74; PMID:8147099; http://dx.doi.org/10.1016/0264-410X(94)90056-6. (Pubitemid 24041936)
13. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:91-5; PMID:15163495; http://dx.doi.org/10.1016/j.virusres.2004.02.019. (Pubitemid 38649066)
14. Stephenson I, Wood JM, Nicholson KG, Zambon MC. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 2003; 70:391-8; PMID:12767002; http://dx.doi.org/10. 1002/jmv.10408. (Pubitemid 36638052)
15. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutinationinhibiting antibody to influenza virus. Dev Biol (Basel) 2003 115:63-73; PMID:15088777.
16. Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007; 25:4056-63; PMID:17412461; http://dx.doi.org/10.1016/j.vaccine.2007.02.039. (Pubitemid 46616989)
17. Bandell A, Woo J, Coelingh K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines 2011; 10:1131-41; PMID:21854309; http://dx.doi.org/10.1586/erv.11.73.
18. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008; 15:1042-53; PMID:18448618; http://dx.doi.org/10.1128/CVI.00397-07. (Pubitemid 352018317)
19. Halliley JL, Kyu S, Kobie JJ, Walsh EE, Falsey AR, Randall TD, et al. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine 2010; 28:3582-7; PMID:20298818; http://dx.doi.org/10.1016/j.vaccine.2010.02.088.
20. Pathirana RD, Bredholt G, Akselsen PE, Pedersen GK, Cox RJA. A(H1N1)pdm09 Vaccination of Health Care Workers: Improved Immune Responses in Low Responders Following Revaccination. J Infect Dis 2012; 206:1660-9; PMID:22969149; http://dx.doi.org/10.1093/infdis/jis589.
21. Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994; 12:993-9; PMID:7975853; http://dx.doi.org/10.1016/0264-410X(94)90334-4. (Pubitemid 24246870)
22. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-80; PMID:22286307; http://dx.doi.org/10.1038/nm.2612.
23. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009; 106:3877-82; PMID:19237568; http://dx.doi.org/10.1073/pnas.0813390106.
24. Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158-66; PMID:22551811; http://dx.doi.org/10.1093/infdis/ jis330.
25. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006 176:6333-9; PMID:16670345.
26. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13-7; PMID:6602294; http://dx.doi.org/10.1056/ NEJM198307073090103. (Pubitemid 13062888)
27. McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, et al. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009; 27:2418-25; PMID:19368783; http://dx.doi.org/10. 1016/j.vaccine.2009.01.136.
28. Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi Viruses 2011; 5:426-37; PMID:21668670; http://dx.doi.org/10.1111/j.1750-2659.2011.00256.x.
29. Vaccine 2011; 29:8049-59; PMID:21864624; http://dx.doi.org/10.1016/j. vaccine.Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 2011; 29:8049-59; PMID:21864624; http://dx.doi.org/10.1016/j.vaccine.2011.08.042.